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Abstract
Purpose Biallelic pathogenic NBAS variants manifest as a multisystem disorder with heterogeneous clinical phenotypes such 
as recurrent acute liver failure, growth retardation, and susceptibility to infections. This study explores how NBAS-associated 
disease affects cells of the innate and adaptive immune system.
Methods Clinical and laboratory parameters were combined with functional multi-parametric immunophenotyping methods 
in fifteen NBAS-deficient patients to discover possible alterations in their immune system.
Results Our study revealed reduced absolute numbers of mature  CD56dim natural killer (NK) cells. Notably, the residual 
NK cell population in NBAS-deficient patients exerted a lower potential for activation and degranulation in response to 
K562 target cells, suggesting an NK cell–intrinsic role for NBAS in the release of cytotoxic granules. NBAS-deficient NK 
cell activation and degranulation was normalized upon pre-activation by IL-2 in vitro, suggesting that functional impair-
ment was reversible. In addition, we observed a reduced number of naïve B cells in the peripheral blood associated with 
hypogammaglobulinemia.
Conclusion In summary, we demonstrate that pathogenic biallelic variants in NBAS are associated with dysfunctional NK 
cells as well as impaired adaptive humoral immunity.
Keywords NBAS · inborn error of immunity · NK cell deficiency · B cell deficiency · vesicle trafficking · familial 
hemophagocytic lymphohistiocytosis
Introduction
NBAS-associated disease is a rare autosomal recessive dis-
order with a broad spectrum of clinical symptoms, mainly 
involving liver, growth, skeletal system, nervous system, 
integument, immune system, and musculature. Biallelic 
pathogenic NBAS variants were first described in an isolated 
Russian population in 2010 causing a syndrome compris-
ing short stature, optic atrophy, and Pelger-Huët anomaly 
(SOPH syndrome; MIM 614800) [1]. In 2015, NBAS vari-
ants were linked to fever-related recurrent acute liver failure 
[infantile liver failure syndrome 2 (ILFS2), MIM 616483] 
[2]. To date, NBAS-associated disease has been documented 
in at least 110 patients from 97 families and NBAS vari-
ants can be classified into three subgroups according to the 
affected part of the protein: “Sec39,” with a predominant 
hepatic phenotype (ILFS2), “C-terminal” with the multisys-
temic SOPH phenotype, and “β-propeller” with a combined 
phenotype (ILFS2-SOPH) [3].
Immunological symptoms and laboratory alterations 
such as frequent infections, hypogammaglobulinemia, low 
natural killer (NK) cell numbers, and neutropenia have 
been observed in more than 60% of patients with NBAS-
associated disease throughout all defined subgroups [3]. 
However, a detailed description of abnormal immunological 
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parameters has only been published in one patient present-
ing with predominant hypogammaglobulinemia who was 
detected by abnormal “κ-deleting recombination excision 
circles” (KREC) via newborn screening [4], suggesting 
NBAS-associated disease to be an inborn error of immunity. 
A systematic analysis of a characteristic immunophenotype 
or altered immunological functionality in NBAS-associated 
disease has remained elusive.
Inborn errors of immunity can present with isolated 
immune cell dysfunction, but can also be part of a multisys-
temic presentation as in DiGeorge syndrome [5], ataxia tel-
eangiectasia [6, 7], or in some forms of familial hemophago-
cytic lymphohistiocytosis (FHL) [8]. Especially with onset 
in early infancy, they can be life-threatening, emphasizing 
the need for early disease recognition, clinical awareness, 
and high throughput genetic testing [9], but also mechanistic 
understanding to improve patient management and care [10].
In this study, we systematically determine key immu-
nological parameters in fifteen individuals with confirmed 
NBAS-associated disease including the cellular composition 
and function of leukocytes in peripheral blood, immuno-
globulin levels, and cytokine gene expression. We reveal that 
NBAS-associated disease displays a common immunologi-
cal signature of impaired humoral adaptive immunity and 
a defective NK cell compartment and, therefore, should be 
considered an inborn error of immunity.
Patients and Methods
Patient Recruitment, Controls, and Data Acquisition
Fifteen patients with biallelic pathogenic variants in NBAS 
from all three subgroups (ILFS2, SOPH, ILFS2-SOPH) 
were included in this prospective observational study. All 
procedures were in accordance with the ethical standards of 
the responsible committee on human experimentation and 
with the Helsinki Declaration of 1975, as revised in 2013. 
Informed consent to participate in the study was obtained 
from all patients or from their parents in the case of minor 
patients. The study was approved by the ethical commit-
tee of the University Hospital Heidelberg and local ethical 
committees.
The general clinical parameters included country of ori-
gin, sex, and age at onset of clinical symptoms. For clinical 
phenotyping, human phenotype ontology terms were used 
(see Supplemental Material). For immunological phenotyp-
ing, blood from all individuals was drawn outside episodes 
of inflammation. If more than one measurement per patient 
was performed, the arithmetic mean was calculated. For flow 
cytometry and gene expression analysis, gender-matched 
and age-matched healthy donors were included. For NK 
cell degranulation assays additional blood samples from six 
patients were obtained and gender-matched healthy donors 
were recruited. Both recruitments took place at the Univer-
sity Hospital Heidelberg. Database was closed on December 
1, 2019.
Gene Expression Analysis
Heparinized whole blood of 0.5 ml was incubated with 
0.1  ml RPMI1640 or stimulated in RPMI1640 with 
100 ng/ml PMA and 5 μg/ml ionomycin (Sigma) for 3 h at 
37 °C and 5%  CO2. Red cells were lysed twice with ACK 
buffer. Afterward, the leukocytes were lysed with 400 μl 
of MagNA-Pure lysis buffer (Roche) containing 1% DTT 
(Roche, cat. no. 10708 984001), and the samples were fro-
zen at − 70 °C. After thawing, the lysates were thoroughly 
mixed and transferred into the MagNA-Pure sample car-
tridge and total RNA was isolated with the MagNA-Pure-
LC device using the RNA standard protocol for cells. The 
elution volume was set to 50 μl. An aliquot of 8.2 μl mRNA 
was reversely transcribed using AMV-RT and oligo-(dT) 
as primers (First Strand cDNA synthesis kit, Roche) in a 
thermocycler according to the manufacture’s protocol. After 
termination of the cDNA synthesis, the reaction mixture was 
diluted to a final volume of 500 μl and stored at − 20 °C until 
PCR analysis.
Primer sets optimized for the LightCycler® (RAS) were 
developed and purchased from SEARCH-LC GmbH (www. 
Search- LC. com). The PCR was performed with the LightCy-
cler® FastStart DNA Sybr Green kit (RAS) according to the 
protocol provided in the parameter-specific kits. To control 
for specificity of the amplification products, a melting curve 
analysis was performed. The copy number was calculated 
from a standard curve, obtained by plotting known input 
concentrations of four different plasmids at log dilutions to 
the PCR-cycle number (CP) at which the detected fluores-
cence intensity reaches a fixed value.
To correct for differences in the content of mRNA, the 
calculated transcript numbers were normalized according 
to the expression of the housekeeping gene peptidylprolyl 
isomerase B (PPIB). Values were thus given as transcripts 
per 1,000 transcripts of PPIB.
Cytokine Measurement
Cytokine measurement was performed by Myriad RBM 
(TX, USA) as follows: Using automated pipetting, an ali-
quot of each sample was added to individual microsphere 
multiplexes of the selected multi-analyte profile (MAP) and 
blocker. This mixture was thoroughly mixed and incubated 
at room temperature for 1 h. Multiplexed cocktails of bioti-
nylated reporter antibodies were added robotically and after 
thorough mixing, incubated for an additional hour at room 
temperature. Multiplexes were labeled using an excess of 
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streptavidin–phycoerythrin solution, thoroughly mixed, 
and incubated for 1 h at room temperature. The volume of 
each multiplexed reaction was reduced by vacuum filtration 
and washed 3 times. After the final wash, the volume was 
increased by addition of buffer for analysis using a Luminex 
instrument, and the resulting data was interpreted using pro-
prietary software developed by Myriad RBM. For each mul-
tiplex, both calibrators and controls were included on each 
microtiter plate. Eight-point calibrators to form a standard 
curve were run in the first and last column of each plate 
and controls at 3 concentration levels were run in duplicate. 
Study sample values for each of the analytes were deter-
mined using 4 and 5 parameter logistics, with weighted and 
non-weighted curve fitting algorithms included in the data 
analysis package.
PBMC Isolation and Culture
Peripheral blood mononuclear cells (PBMCs) were isolated 
from unfractionated peripheral blood by Ficoll-Hypaque 
density gradient (density 1.077 g/ml, Biochrom, VWR) cen-
trifugation. For functional and phenotypic analyses, PBMCs 
were resuspended in SCGM medium (CellGenix) containing 
10% human serum (pooled human AB serum, # P041702, 
Pan-Biotech) and cultured for 2 days without or with 400 U/
ml of IL-2 (kindly provided by the NIH, USA).
Degranulation
CD107a upregulation on NK cells of NBAS-deficient 
patients or healthy controls was measured after co-culture 
of NK cells without or with the erythroleukemic cell line 
K562 (ATCC) at 1:1 ratio (each 5 ×  104 cells) in duplicate 
for 4 h in the presence of anti-CD107a FITC (clone A4A3, 
Biolegend) or anti-CD107a PE (clone A4A3, Biolegend, 
and GolgiPlug, 1/100 v/v, BD Bioscience) in 96-well plates 
in RPMI 1640 (Invitrogen) supplemented with heat-inacti-
vated 10% FCS (Invitrogen) and 1% penicillin/streptomycin 
(Sigma-Aldrich).
Flow Cytometry
The immunophenotyping was performed in whole blood. 
Absolute cell count was measured using the BDMultitest™ 
6-color TBNK reagent with BD Trucount™tubes (BD Bio-
sciences, Heidelberg, Germany). The panels are modified 
recommendations of the “Human Immunophenotyping con-
sortium” [11]. Briefly, Panel-1 consisted of 17 antibodies to 
characterize the major T cell populations, including naïve 
and various memory/effector populations (CD2; CD3; CD4; 
CD8; TCR ƴδ; CD45RA; CD197 (CCR7); CD28; CD57 
and CD127). Th1, Th2; Th17, and Tfh cells were identified 
with the following antibodies: CD183 (CXCR3); CD185 
(CXCR5); and CD196 (CCR6). Activation was monitored 
with antibodies against HLA-DR, CD38, CD278 (ICOS), 
and CD279 (PD1). Using CD3 as a backbone for absolute 
quantification, with this comprehensive panel more than 
200 defined subpopulations have been quantified in abso-
lute numbers as well as in various ratios. Panel-2 consists of 
8 parameters (CD3; CD19; CD20; anti-IgD; CD27; CD10; 
CD24; and CD38), allowing the identification of transitional, 
naïve, and memory B cells as well as circulating plasma-
blasts both in absolute numbers (CD19 backbone) and in 
various ratios. Panel-3 identified various NK, monocyte 
and DC subsets and included antibodies with the following 
specificities: CD11c; CD123; CD14; CD16; CD19; CD2; 
CD20; CD25; CD3; CD45; CD56; CD57; CD8a; HLA-DR; 
and M-DC8. Using NK cells as backbone, absolute num-
bers were calculated for 50 different populations. Finally, 
the Treg subset was characterized using the following anti-
bodies: CD127; CD194 (CCR4); CD25; CD3; CD4; CD45; 
CD45RO; and anti-HLA-DR. CD4 + T-lymphocytes served 
as backbone for the absolute quantification of the different 
subsets. The analysis was performed on an LSR Fortessa 
Analyzer (Special Order Research Product) (BD Bio-
sciences). The detailed setup, staining, gating, and analysis 
procedures have been recently described [12]. Cell surface 
expression of CD107a and CD69 (marker for NK cell activa-
tion) and intracellular expression of perforin and granzyme 
B of  CD3−  CD56+ NK cells in PBMCs was measured by 
flow cytometry (LSR Fortessa II, BD Bioscience) and ana-
lyzed with FlowJo 10 software (FlowJo LLC). Intracellular 
staining was performed using the “Cytofix/Cytoperm” kit 
(BD Bioscience). (For information on antibodies, see Sup-
plemental Material.)
Statistics
Statistical analyses were performed with GraphPad Prism. 
Mean values of two groups were compared by Mann–Whit-
ney U-tests. Mean values of multiple groups were assessed 
by one-way ANOVA followed by multiple comparisons 
post hoc tests as indicated. Error bars represent the SEM 
and asterisks indicate the significance levels (*P < 0.05; 
**P < 0.01; ***P < 0.001). The correlation coefficient R2 
was calculated by linear regression.
Results
Genotype and Clinical Phenotype
Fifteen patients from 14 unrelated families carrying 19 dif-
ferent NBAS variants (Supplemental Fig. 1A) were included 
in this study. All three NBAS deficiency subgroups were 
represented (“β-propeller” n = 4; “Sec39” n = 5; “C-terminal 
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n = 4”; not attributable to one of the subgroups n = 2) 
(Table 1). Clinical presentations of 14 of those patients have 
been reported previously [3, 4], whereas individual NBAS 
88 has not been reported before. Thirteen patients originated 
from European countries, one patient from the USA, and 
one from Saudi Arabia. The median age at last assessment 
was 7 years (range: 0.4–43 years). First symptoms occurred 
in all patients within the first 2 years of life and consisted 
of acute liver failure or elevated liver transaminases in most 
cases (73%). Only individual NBAS 88 was diagnosed pre-
natally and showed immunological laboratory abnormalities 
and slightly elevated liver transaminases at 8 months of age 
when the database was closed.
All patients had immunological and hepatic features, 
while other organ affections were present to different extents 
according to their NBAS deficiency subgroup (Table 1 
[3]). One prominent finding throughout all subgroups was 
the occurrence of recurrent infections (reported in 10/15 
patients). These infections were mostly common with 
respect to localization and pathogens (Table 2), but inten-
sity suggested a pathological susceptibility in some patients 
when assessed following the national guideline for clinical 
diagnostics of inborn errors of immunity [13].
Immunoglobulins Are Reduced in NBAS‑Deficient 
Patients
To assess adaptive humoral abnormalities in NBAS-deficient 
patients, we examined serum immunoglobulin (Ig) levels. 
Ig levels of classes M, G, and A were reduced in 10 of the 
15 patients, with consistently low IgG being most prevalent 
(n = 8; age at diagnosis: 2 months until 7 years, median: 
7.5 months; Table 2). All patients from the “C-terminal” 
subgroup had low IgG. Six patients with consistently low 
IgG received Ig replacement therapy, resulting in a reduction 
of infections. Five patients showed insufficient responses to 
vaccination when tested sporadically, but also after sched-
uled vaccinations in 3 patients, pointing to an impaired adap-
tive humoral immune responsiveness (Table 2). Comparing 
the B cell phenotype of those patients with impaired Ig lev-
els of all tree classes with those patients with normal levels 
of Ig, the relative number of transitional B cells seems to be 
increased (22.22 ± 10.44 vs. 6.73 ± 3.73; P = 0.034), pointing 
to delayed B cell maturation in the patients with humoral 
immunodeficiency. Differences in B cell subpopulations 
between patients with specific Ig isotype deficiencies could 
not be observed.
CD56+ NK Cells and  CD19+‑Naïve B Cells Are 
Reduced in NBAS‑Deficient patients
To analyze the composition of cellular immunity, periph-
eral blood leukocyte subsets were quantified. The majority 
of NBAS-deficient patients showed a consistent reduction 
in  CD56+ NK cells, resulting in > 50% lower absolute NK 
cell numbers relative to healthy controls (Fig. 1A–B and 
Supplemental Fig. 1B). This reduction in  CD56+ NK cells 
was maintained over time in 8 of 15 patients, who could be 
assessed at two to five time points over a period of 8 to up 
to 1100 days after the first visit/measurement (Supplemental 
Fig. 1C). Naïve  CD19+ B cell numbers were considerably 
lower and correlated with the reduction in NK cells in most 
patients. Frequencies of other leukocyte subsets or B cell 
subsets were reduced to a lower extent or were heterogene-
ous (Fig. 1B, Supplemental Fig. 1B and D).
Next, the gene expression status of immune cell–secreted 
molecules in leukocytes (no subsets) was measured. The 
expression of key cytokines such as IL-2, IFN-γ, and TNF 
was not altered in steady state or after stimulation with 
PMA/ionomycin compared to healthy controls. Blood 
cytokine levels of IL-2, IFN-γ, and TNF did not differ 
between patients and controls (data not shown). Altogether, 
the quantification of leukocyte subsets revealed a significant 
reduction in NK cells and naïve B cells as the most consist-
ent cellular biomarker of immune deficiency.
The CD56DIM CD16 + NK Cell Subset Is Reduced 
in NBAS‑Deficient Patients
To extend the phenotypic characterization of NK cells in 
NBAS-deficient patients, we analyzed the percentage of NK 
cell subsets within PBMCs. The percentage of the  CD56dim 
 CD16+ NK cell subset was significantly reduced in NBAS-
deficient patients compared to healthy controls (Fig. 2A). 
The decrease of the percentage of  CD56dim  CD16+ NK cells 
was paralleled by the reduction of the absolute cell number 
of the  CD56dim  CD16+ NK cell subset, whereas the absolute 
cell number of the  CD56bright  CD16− NK cell subset was 
unchanged (Fig. 2B). Hence, the reduction in NK cells in 
PBMCs of NBAS-deficient patients was a consequence of 
the reduction in the  CD56dim  CD16+ NK cell subset.
NBAS‑Deficient NK Cells Are Hyporesponsive 
to Target Cell Stimulation
NBAS transcripts have been detected in numerous human tis-
sues including blood [14], and NBAS protein was detected in 
primary NK cells and NK cell lines (Supplemental Fig. 1E); 
hence, NBAS deficiency could have an intrinsic effect on 
NK cell biology.
We investigated whether the remaining NK cells in 
NBAS-deficient patients retained responsiveness to the 
prototypical target cell line K562 by measuring CD107a 
upregulation on NK cells as a functional marker for cytol-
ytic granule release (Fig. 3A–B). For this functional analy-
sis, blood samples could be obtained from six patients that 
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belonged to the “β-propeller” and the “Sec39” subgroup, but 
not from patients from the “C-terminal” subgroup. CD107a 
upregulation on NK cells was tested outside inflammatory 
episodes or liver decompensations. The mean percentage of 
 CD107a+ NK cells of NBAS-deficient patients in response 
to K562 cells was considerably decreased, resulting in an 
approx. 50% reduction in CD107a upregulation as compared 
to NK cells from healthy controls (Fig. 3B). The reduction in 
CD107a upregulation was apparent in both the  CD56dim and 
the  CD56bright NK cell populations. Accordingly, the reduc-
tion in peripheral blood NK cell numbers was accompanied 
by a reduced responsiveness of the NK cells in NBAS-
deficient patients. Intracellular perforin protein expression 
in NK cells was lower in NBAS-deficient patients but did 
not reach statistical significance, while granzyme B lev-
els were unchanged (Fig. 3C). In conclusion, the reduced 
NK cell population in NBAS-deficient patients appeared 
to be less responsive to target cell stimulation in terms of 
degranulation.
IL‑2 Activation Rescues the Responsiveness 
of NBAS‑Deficient Patients’ NK Cells
Next, we assessed whether functionality of patients’ NK 
cells can be improved by the NK cell-activating cytokine 
IL-2 (Fig.  4A) in  vitro. Exposure to IL-2 for 2  days 
induced upregulation of the early activation marker CD69 
on the cell surface of NBAS-deficient NK cells, but still 
Fig. 1  Circulating CD56 + NK cells are reduced in NBAS patients. 
B Absolute cell numbers of leukocytes subsets per microliters of 
peripheral blood were quantified in fifteen NBAS patients relative 
to a group of twelve healthy controls by flow cytometry. Indexed 
patients were tested throughout this study in phenotypic and func-
tional assays. B Gene expression was determined in whole blood of 
NBAS patients or healthy controls in steady state or after 3-h stimula-
tion with PMA and ionomycin
 Journal of Clinical Immunology
1 3
to a lower extend than observed in healthy control NK 
cells (Supplemental Fig. 2A). Importantly, IL-2-exposed 
NK cells of NBAS-deficient patients showed enhanced 
CD107a upregulation in response to K562, which was sim-
ilar to that of IL-2-exposed NK cells from healthy controls 
(Fig. 4B). Activation by IL-2 substantially improved NK 
cell degranulation even of those patient cells which were 
very weak responders to K562 without IL-2 pre-activation 
(i.e., patients 2, 60, and 88). Congruent with the higher 
activation potential, patients exhibiting high CD107a 
upregulation also showed higher CD69 expression (Sup-
plemental Fig. 2B). Moreover, intracellular perforin and 
granzyme B protein expression levels were increased and 
similar between IL-2-exposed NK cells of NBAS-defi-
cient patients and healthy controls (Fig. 4C). Thus, IL-2 
cytokine-induced activation can rescue the functionality 
of NBAS-deficient patient NK cells and their responsive-
ness to target cells.
Discussion
NBAS-associated disease is a complex disorder with a 
heterogeneous clinical spectrum involving multiple organ 
systems that can be categorized into three different clini-
cal subgroups “β-propeller,” “Sec39,” and “C-terminal” 
[3]. Abnormalities of the immune system are present in a 
majority of NBAS-deficient individuals of all three sub-
groups [3], but no detailed characterization of this affec-
tion has been done so far. In this study, we demonstrate 
that the immunodeficiency phenotype of NBAS-associated 
disease is characterized by quantitative and qualitative NK 
cell and B cell deficiency. The lower NK cell counts cor-
related with the loss of the more mature CD56dim  CD16+ 
cytotoxic NK cell subset, pointing toward dysfunctional 
NK cell maturation and/or disrupted mature NK cell 
homeostasis. The residual NK cell population exerted a 
significantly lower potential for activation and degranula-
tion upon contact with K562 target cells. This hyporespon-
sive state could be rescued in vitro by pre-activation with 
the NK cell-stimulating cytokine IL-2. Due to a lack of 
available biosamples, functional analysis of NK cells was 
tested in patients from the “β-propeller” and the “Sec39” 
subgroup, but not in patients from the “C-terminal” group.
Altered NK cell development and numbers of NK cells 
and ensuing susceptibility to herpes or papilloma virus 
infections are hallmarks of classical NK cell deficiencies 
[15]. Importantly, patients with NBAS-associated disease 
suffer from frequent and recurrent infections (Table 2 and 
authors’ unpublished data) such as human herpesvirus 
6-associated severe crisis of NK cell depletion and liver 
failure in individual NBAS 60. In addition, susceptibility 
of NBAS-deficient patients to viral infections may also be 
facilitated by defective humoral immunity, since consist-
ently low IgG serum levels and partially impaired specific 
antibody generation after vaccination were prevalent in 
these patients [3].
Among classical NK cell deficiencies, the most fre-
quently cited defect, GATA2 deficiency, affects  CD56bright 
NK cells [16], while NK cell deficiencies due to variants 
in IRF8 and MCM4 mainly affect  CD56dim NK cells and 
present with impaired cytolytic function, similar to the 
pattern observed in our patients [17, 18].
Dysfunctional NK cell degranulation is one of the diag-
nostic parameters of hemophagocytic lymphohistiocyto-
sis (HLH) which is a life-threatening hyperinflammatory 
syndrome. HLH has been categorized into primary FHL, 
syndromic HLH, and secondary HLH mainly driven by 
infections. Primary HLH itself is characterized by uncon-
trolled activation of lymphocytes and macrophages due 
to impaired cytotoxic function of NK cells and T cells, 
leading to excessive cytokine production like IFN-γ [19]. 
Fig. 2  The reduction in NK cells is due to the low numbers of the 
 CD56dim NK cell subset. A The percentage of  CD56bright and 
 CD56dim NK cell subsets within  CD56+ NK cells was measured by 
flow cytometry. B Absolute cell numbers per microliters of peripheral 
blood of  CD56bright and  CD56dim NK cell subsets
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While the cytotoxic potential of NK cells in NBAS-
deficient patients from the “β-propeller” and “Sec39” 
subgroup was likewise reduced, we did not observe 
increased pro-inflammatory cytokine levels in serum of 
NBAS-deficient patients in remission. However, no data 
on cytokine levels or the status of myeloid cell activation 
during inflammatory states or, of specific interest, during 
episodes of liver failure were available.
Systemic hyperinflammation in the context of HLH is a 
major cause of acute liver failure in the first year of life [20, 
21]. However, there is growing evidence that dysregulated 
hepatic inflammation per se can lead to acute liver failure 
[22, 23] and NBAS-deficient patients from the “β-propeller” 
and “Sec39” subgroup have fever-related acute liver failure 
[3]. As elevated temperature was shown to cause a reduc-
tion in NBAS protein level and cell viability [24], fever 
might affect NK cell homeostasis and viability particularly 
in NBAS-deficient cells. In line with this is the observation 
that absolute NK cell numbers further decreased in indi-
viduals NBAS 8 and NBAS 60 under the level of detection 
during febrile episodes (data not shown). However, NK cells 
were low in number and dysfunctional also outside episodes 
of inflammation or hepatic dysfunction. There may be evo-
lution of the immune phenotype in NBAS-associated over 
life time, which could be one explanation for the immune-
phenotypic inconsistency among siblings sharing the same 
genotype (NBAS 60, NBAS 88). Further studies are needed 
to study NK cell activation, cell signaling of the JAK-STAT 
pathways [23], cytokine secretion, such as IL-18, and IL-
18BP [22], and degranulation in NBAS deficiency especially 
during fever-triggered acute liver failure. This might set the 
stage of targeted treatment of NBAS deficiency associate 
acute liver failure, e.g., with Janus kinase inhibitors [25] 
or IL-18 binding protein (ClinicalTrials.gov Identifier: 
NCT03113760).
Apart from a hepatic phenotype, the FHL, and syndromic 
HLH can include growth retardation, neurological dysfunc-
tion [26–28] and hypogammaglobulinemia (FHL5 [29], 
Griscelli syndrome type 2 [20, 30], XLP-1 deficiency, and 
XPL-2/XIAP deficiency [31]), all of which are prevalent 
Fig. 3  Residual NK cells in NBAS patients are functionally impaired 
upon activation by K562 cells. A Scheme of the experimental setup. 
B NK cell degranulation, indicated by the percentage of  CD107a+ 
cells of  CD56+ NK cells, was measured by flow cytometry after 4-h 
co-culture of NBAS patients’ or healthy controls’ NK cells with K562 
target cells. Baseline  CD107a+ in the absence of K562 cells was sub-
tracted. Combined data, comparing the mean of six patients to that 
of healthy controls, and representative FACS contour plots of one 
patient and healthy control combination are depicted (limits were set 
according to CD107a expression in the absence of K562 cells and 
distinguishing  CD56bright and  CD56dim NK cell subsets). C Intracellu-
lar protein expression of perforin and granzyme B in NK cells, which 
had not been co-cultured with K562 target cells, was measured by 
flow cytometry (geometric mean fluorescence intensity, gMFI). Iso-
type control staining was subtracted. Combined data, comparing the 
mean of five patients to that of healthy controls, and representative 
FACS histograms of one patient (red line) and healthy control (blue 
line) combination are depicted
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in NBAS deficiency [3]. Thus, HLH and NBAS-associated 
disease share clinical symptoms and immunological abnor-
malities (Table 3).
FHL2-5 and syndromic HLH share a pathophysiology 
of defective biogenesis and trafficking of cytolytic vesi-
cles including their priming and fusion with the plasma 
Fig. 4  NK cell dysfunction of 
NBAS patients can be rescued 
by pre-activation with IL-2. A 
Scheme of the experimental 
setup. B NK cell degranulation, 
indicated by the percentage 
of  CD107a+ cells of  CD56+ 
NK cells, was measured and 
analyzed as described in Fig. 3. 
In the representative FACS con-
tour plots, limits were for total 
 CD56+ NK cells due to blurred 
distinction of  CD56bright and 
 CD56dim NK cell subsets upon 
IL-2 treatment. C Intracellular 
protein expression of perforin 
and granzyme B in NK cells 
was determined and analyzed as 
described in Fig. 3
Table 3  FHL and HLH syndromes: genes, functions, and cytometric abnormalities
FHL, familial hemophagocytic lymphohistiocytosis; HLH, hemophagocytic lymphohistiocytosis; ILFS2, infantile liver failure syndrome type 2; 
SOPH, short stature, optic nerve atrophy, Pelger-Huët anomaly
Disease name Phenotype MIM 
number(s)
Affected gene Affected cellular function Flow cytometric abnor-
mality
FHL FHL1 267700 Unknown Unknown Not available
FHL2 603553 PRF1 Pore formation Decreased / absent perforin 
expression
FHL3 608898 UNC13D Vesicle priming Decreased CD107a expres-
sion
FHL4 603552 STX11 Vesicle fusion Decreased CD107a expres-
sion
FHL5 601717 STXBP2 Vesicle fusion Decreased CD107a expres-
sion
















616483; 614800 NBAS Vesicle trafficking Decreased CD107a expres-
sion
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membrane (Table 3 [8]). The Sec39 domain of NBAS is 
part of the syntaxin 18 (STX18) complex, a soluble N-eth-
ylmaleimide-sensitive-factor attachment receptor (SNARE) 
complex involved in anterograde and retrograde transport 
between endoplasmic reticulum and Golgi [2, 24, 32, 33]. 
Additionally, STX18 has been shown to directly interact 
with syntaxin 4 (STX4), a known mediator of degranula-
tion of cytolytic vesicles that is located at the plasma mem-
brane [34, 35]. While degranulation activity of NK cells 
is decreased in NBAS-deficient patients, expression levels 
of granzyme B and perforin remain widely unchanged. We 
speculate that impaired STX18 complex function in NBAS-
associated disease might impair NK cell cytotoxicity by dis-
turbing granule release of cytotoxic vesicles. More globally 
and since STX4 is known to be involved in IgG exocytosis, 
insulin secretion and glucose uptake in the musculature and 
adipose tissue, a dysfunctional interaction between STX4 
and STX18 might be a driver not only for hypogamma-
globulinemia but also for diabetes mellitus type 1, muscular 
hypotonia, and reduced subcutaneous fat tissue, which are 
all found in NBAS-associated disease [36]. Other diseases 
affecting STX18 complex function such as RINT1 defi-
ciency, which is associated with recurrent liver failure and 
skeletal abnormalities and hence shows phenotypic overlap 
to NBAS deficiency, should be investigated for trafficking 
of cytolytic vesicles and impaired NK cell cytotoxicity [37].
We show that NK cell activation and degranulation were 
improved by pre-activation of NK cells with IL-2 in vitro 
in patients from the “β-propeller” and “Sec39” subgroup, 
suggesting that IL-2 might enhance NBAS expression and/
or function or promote alternative molecular pathways 
mediating cytolytic vesicle release in those. Similarly, 
NK cell degranulation was shown to be improved after 
48–72-h IL-2 stimulation in NK cells of FHL4 patients 
due to variants in STX11 and FHL5 due to variants in 
STXBP2, with both genes coding for SNARE proteins [29, 
38]. Hence, cytokine therapy with clinically approved IL-2 
or IL-15 formulations [36, 39, 40] might support NK cell 
function in NBAS-deficient patients. Clearly, future in-
depth mechanistic studies are warranted to better under-
stand the complex pathophysiology of NBAS deficiency.
In conclusion, NBAS variants cause a multisystem dis-
ease including an immunodeficiency phenotype marked 
by low NK cell numbers and NK cell dysfunction as well 
as reduction of naïve B cells and serum immunoglobulin 
levels. Patients with pathogenic NBAS variants should be 
investigated accordingly.
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